Advertisement

Cancer Immunology, Immunotherapy

, Volume 59, Issue 5, pp 789–797 | Cite as

Activation of innate immunity to reduce lung metastases in breast cancer

  • Julie L. JordanEmail author
  • A. Nowak
  • T. D. G. Lee
Original Article

Abstract

Breast cancer continues to be one of the leading causes of cancer death in women. Mortality is primarily due to the development of metastases. Although therapies exist, they lack efficacy in preventing metastatic growth. As a result, novel agents are being investigated. In particular, treatments that target the immune system are being examined as potential anti-neoplastic agents. Cordyceps sinensis (Cs) is a fungus that has been used for over 2,000 years in China as a treatment for a variety of conditions including neoplasms. The available evidence suggests that efficacy of Cs as an anti-neoplastic therapeutic agent is related to a role as an activator of innate immune responses. The objectives of this study were: to investigate the ability of Cs to activate macrophages to produce factors that will induce protective responses against tumour growth; to study the ability of Cs to reduce primary tumour growth in vivo; and to examine the ability of Cs to reduce lung metastasis growth in vivo. We found that oral Cs does not reduce primary tumour growth but can reduce lung metastasis occurrence in a surgical excision model of metastatic mammary carcinoma. The evidence we have shown to date suggests that the reduction in metastases growth may be due to the effects of macrophage-derived factors on tumour cell cycle.

Keywords

Innate immunity Breast cancer Macrophages Cell cycle Metastases Cordyceps sinensis 

Notes

Acknowledgments

This work was supported by the Canadian Breast Cancer Foundation (CBCF), Atlantic Chapter.

Conflict of interest statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

  1. 1.
    Al-Moundhri M, O’Brien M, Souberbielle BE (1998) Immunotherapy in lung cancer. Br J Cancer 78:282–288PubMedGoogle Scholar
  2. 2.
    American Cancer Society. Breast cancer facts and figures 2007–2008. American Cancer Society, AtlantaGoogle Scholar
  3. 3.
    Armstrong A, Eaton D, Ewing J (2001) Cellular immunotherapy for cancer. Br Med J 323:1289–1293CrossRefGoogle Scholar
  4. 4.
    Bach JP, Deuster O, Balzer-Geldsetzer M et al (2009) The role of macrophage inhibitory factor in tumourigenesis and central nervous system tumors. Cancer 115:2031–2040CrossRefPubMedGoogle Scholar
  5. 5.
    Breder J, Rüller S, Rüller E, Schlaak M, van der Bosch J (1996) Induction of cell death by cytokines in cell cycle-synchronous tumour cell populations restricted to G1 and G2. Exp Cell Res 223:259–267CrossRefPubMedGoogle Scholar
  6. 6.
    Cameron DJ, Churchill WH (1980) Cytotoxicity of human macrophages for tumour cells: enhancement by bacterial lipopolysaccharides (LPS). J Immunol 124:708–712PubMedGoogle Scholar
  7. 7.
    Chen YJ, Shiao MS, Lee SS, Wang SY (1997) Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells. Life Sci 60(25):2349–2359CrossRefPubMedGoogle Scholar
  8. 8.
    Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739–1742CrossRefPubMedGoogle Scholar
  9. 9.
    Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ (1984) Cell cycle-specific effects of tumour necrosis factor. Cancer Res 44:83–90PubMedGoogle Scholar
  10. 10.
    Dickens DS, Jubinsky PT (2009) Therapeutic strategies for targeting mononuclear phagocytes in cancer. J Pediatr Hematol Oncol 31:14–17CrossRefPubMedGoogle Scholar
  11. 11.
    Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141:2407–2412PubMedGoogle Scholar
  12. 12.
    Doe WF, Henson PM (1978) Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumour target cells. J Exp Med 148:544–556CrossRefPubMedGoogle Scholar
  13. 13.
    Drapier JC, Hibbs JB Jr (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumour cells results in l-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 140:2829–2838PubMedGoogle Scholar
  14. 14.
    Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55–S57PubMedGoogle Scholar
  15. 15.
    Gale DM, Sorokin P (2001) The interleukins. In: Trahan P (ed) Biotherapy. A comprehensive overview. Jones and Bartlett, London, pp 195–244Google Scholar
  16. 16.
    Grande C, Firvida JL, Navas V, Casal J (2006) Interleukin-2 for the treatment of solid tumours other than melanoma and renal cell carcinoma. Anticancer Drugs 17:1–12CrossRefPubMedGoogle Scholar
  17. 17.
    Guarneri V, Conte PF (2004) The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 31(Suppl 1):S149–S161CrossRefPubMedGoogle Scholar
  18. 18.
    Hattori Y, Szabó C, Gross S, Thiemermann C, Vane JR (1995) Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. Eur J Pharmacol 291:83–90CrossRefPubMedGoogle Scholar
  19. 19.
    Henry Y, Lepoivre M, Drapier JC, Ducrocq C, Boucher JL, Guissani A (1993) EPR characterization of molecular targets for NO in mammalian cells and organelles. FASEB J 7:1124–1134PubMedGoogle Scholar
  20. 20.
    Jordan JL, Sullivan AM, Lee TDG (2008) Immune activation by a sterile aqueous extract of Cordyceps sinensis: Mechanism of Action. Immunopharmacol and Immunotoxicol 30:53–70CrossRefGoogle Scholar
  21. 21.
    Jubinsky PT, Dickens DS, Short MK (2008) New roles for mononuclear phagocytes in cancer biology. J Pediatr Hematol Oncol 30:584–591CrossRefPubMedGoogle Scholar
  22. 22.
    Kiener PA, Marek F, Rodgers G, Lin PF, Warr G, Desiderio J (1988) Induction of tumour necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol 141:870–874PubMedGoogle Scholar
  23. 23.
    Kröncke KD, Fehsel K, Schmidt T et al (1988) Nitric oxide destroys zinc–sulfur clusters inducing zinc release from metallothionein and inhibition of the zinc finger-type yeast transcription activator LAC9. Biochem Biophys Res Commun 200:1105–1110CrossRefGoogle Scholar
  24. 24.
    Lee CH, Wu CL, Shiau AL (2008) Toll-like receptor 4 mediators an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res 14:1905–1912CrossRefPubMedGoogle Scholar
  25. 25.
    Lien EJ (1990) Fungal metabolites and Chinese herbal medicine as immunostimulants. Prog Drug Res 34:395–420PubMedGoogle Scholar
  26. 26.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487–1489CrossRefPubMedGoogle Scholar
  27. 27.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA (1986) Antitumour efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumour escape in mice undergoing immunotherapy. Cancer Res 46:676–683PubMedGoogle Scholar
  28. 28.
    Mulé JJ, Shu S, Rosenberg SA (1985) The anti-tumour efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135(1):646–652PubMedGoogle Scholar
  29. 29.
    Poltorak A, He XL, Smirnova I et al (1998) Limits of a deletion spanning TLR4 in C57BL/10ScCr mice. Science 282:2085–2088CrossRefPubMedGoogle Scholar
  30. 30.
    Richter C, Gogvadze V, Schlapbach R, Schweizer M, Schlegel J (1994) Nitric oxide kills hepatocytes by mobilizing mitochondrial calcium. Biochem Biophys Res Commun 205:1143–1150CrossRefPubMedGoogle Scholar
  31. 31.
    Robbins PF, Dudley ME, Wunderlich J et al (2004) Cutting Edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173(12):7125–7130PubMedGoogle Scholar
  32. 32.
    Saha DC, Astiz ME, Lin RY, Rackow EC, Eales LJ (1997) Monophosphoryl lipid A stimulated up-regulation of nitric oxide synthase and nitric oxide release by human monocytes in vitro. Immunopharmacology 37:175–184CrossRefPubMedGoogle Scholar
  33. 33.
    Shih S-C, Stutman O (1996) Cell cycle-dependent tumour necrosis factor apoptosis. Cancer Res 56:1591–1598PubMedGoogle Scholar
  34. 34.
    van der Bosch J, Rüller E, Ernst M et al (1992) Cytokines involved in monocyte mediated tumour cell death and growth inhibition in serum-free medium. J Cell Physiol 152:617–625CrossRefPubMedGoogle Scholar
  35. 35.
    Wan JM, Fogt F, Bistrian BR, Istfan N (1993) Evaluation of antitumour effect of tumour necrosis factor in terms of protein metabolism and cell cycle. Am J Physiol 265:C365–C374PubMedGoogle Scholar
  36. 36.
    Wolska A, Lech-Marańda E, Robak T (2009) Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 14:248–272CrossRefPubMedGoogle Scholar
  37. 37.
    Wolska A, Lech-Marańda E, Robak T (2009) Toll-like receptors and their role in hematologic malignancies. Curr Mol Med 9:324–335CrossRefPubMedGoogle Scholar
  38. 38.
    Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132CrossRefPubMedGoogle Scholar
  39. 39.
    Yoshida J, Takamura S, Yamaguchi N et al (1989) Antitumour activity of an extract of Cordyceps sinensis (Berk.) Sacc. against murine tumour cell lines. Jpn J Exp Med 59(4):157–161PubMedGoogle Scholar
  40. 40.
    Zhang Z, Xia SS (1990) Cordyceps sinensis-I as an immunosuppressant in heterotopic heart allograft model in rats. J Tongji Med Univ 10(2):100–103PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Pathology, Atlantic Centre for Transplantation ResearchDalhousie UniversityHalifaxCanada
  2. 2.Department of Microbiology and Immunology, Atlantic Centre for Transplantation ResearchDalhousie UniversityHalifaxCanada
  3. 3.Department of Surgery, Faculty of Medicine, Atlantic Centre for Transplantation ResearchDalhousie UniversityHalifaxCanada

Personalised recommendations